These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 15026561

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure.
    Chen YT, Wang Y, Radford MJ, Krumholz HM.
    Am Heart J; 2001 Mar; 141(3):410-7. PubMed ID: 11231438
    [Abstract] [Full Text] [Related]

  • 4. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure.
    Kazi D, Deswal A.
    Cardiol Clin; 2008 Feb; 26(1):1-14, v. PubMed ID: 18312901
    [Abstract] [Full Text] [Related]

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Role of angiotensin-converting enzyme inhibitors in the treatment of heart failure in the 21st century].
    Gibelin P.
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):41-5. PubMed ID: 11933555
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 9. Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community.
    Rochon PA, Sykora K, Bronskill SE, Mamdani M, Anderson GM, Gurwitz JH, Gill S, Tu JV, Laupacis A.
    J Gen Intern Med; 2004 Jun; 19(6):676-83. PubMed ID: 15209607
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 12. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Jan; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 13. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
    Tang WH, Vagelos RH, Yee YG, Fowler MB.
    Am Heart J; 2004 Nov; 148(5):889-94. PubMed ID: 15523323
    [Abstract] [Full Text] [Related]

  • 14. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
    Lévy S.
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
    [Abstract] [Full Text] [Related]

  • 15. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I, Rubonivich S, Azaz-Livshits T.
    Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
    [Abstract] [Full Text] [Related]

  • 16. [Management of the treatment with converting enzyme inhibitors in chronic heart failure].
    Zannad F.
    Rev Prat; 1992 Dec 15; 42(20):2563-7. PubMed ID: 1299941
    [Abstract] [Full Text] [Related]

  • 17. [Effects of angiotensin converting enzyme inhibitor with different doses on plasma brain natriuretic peptide and norepinephrine in patients with chronic heart failure].
    Song HM, Zhang J, Deng B, Luo M.
    Zhonghua Yi Xue Za Zhi; 2005 Jul 06; 85(25):1737-40. PubMed ID: 16253158
    [Abstract] [Full Text] [Related]

  • 18. Challenging the dogma of high target doses in the treatment of heart failure: is more always better?
    Follath F.
    Arch Cardiovasc Dis; 2009 Nov 06; 102(11):785-9. PubMed ID: 19944395
    [Abstract] [Full Text] [Related]

  • 19. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
    Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J.
    Eur Heart J; 2005 Oct 06; 26(20):2154-8. PubMed ID: 16014644
    [Abstract] [Full Text] [Related]

  • 20. Combining aspirin with angiotensin converting enzyme inhibitors in heart failure: how safe is it?
    Mehta H, Mahajan A, Bansal N, Vaidya S, Pathak L.
    J Assoc Physicians India; 1998 Nov 06; 46(11):953-6. PubMed ID: 11229224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.